Novel JAK Inhibitor Shows Efficacy over 48 Weeks of Treatment for Long-Term Control of Rheumatoid Arthritis

Phase 3 Data with New JAK Inhibitor in Rheumatoid Arthritis Predicts Evolving Sequence of Therapies

Oral JAK Inhibitors May Displace Injectable Biologics in Treatment of Rheumatoid Arthritis

Patient Support Program Helps Sustain Low Disease Activity on TNF Inhibitor Therapy

bDMARDs Improve Vascular Function in Treatment-naïve Patients with Early Rheumatoid Arthritis

Early Knee, Jaw, Wrist, or Elbow Swelling Associated with Worse Rheumatoid Arthritis Prognosis

JAK Inhibitors Test Specificity of Action in Rheumatoid Arthritis

Psoriatic Arthritis Remains Controlled on Anti-IL-17 Agents out to Three Years

Emerging Options: Moving Toward JAK1 Selectivity in Rheumatoid Arthritis

Expansion in Biologic Option Critical For Non-Responders to TNF Inhibitors